Research
Hormonal
Sibutramine was withdrawn from the market because long-term use increases the risk of non-fatal myocardial infarction and stroke in patients with cardiovascular risk factors.
Sibutramine is no longer available because it increases the risk of heart attack and stroke in people with existing heart conditions. It was withdrawn from the market in 2010.
StrongRefutesVERY_HIGH confidence
Long-term sibutramine treatment was shown to increase the risk of non-fatal myocardial infarction and nonfatal stroke, but not of cardiovascular death or death from any cause in overweight or obese patients with pre-existing cardiovascular diseases.
Why this rating
Based on the large SCOUT trial (10,742 patients) and subsequent regulatory actions.
Source
Anti-Obesity Drugs: A Review about Their Effects and Safety
Jun Goo Kang et al. · Diabetes & Metabolism Journal · 2012
DOI 10.4093/dmj.2012.36.1.13
narrative_reviewCited 587×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Orlistat is the only currently available anti-obesity drug for long-term management due to its favorable cardiovascular safety profile compared to withdrawn agents like sibutramine and rimonabant.Good
- Rimonabant, a CB1 receptor antagonist, was withdrawn due to an increased risk of serious psychiatric adverse events, including depression and suicidal ideation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →